G Medical Innovations Holdings Ltd (ASX:GMV) has been granted a trading halt by the ASX pending an announcement in respect of the receipt of material purchase orders for the supply of products into the US territory.
The halt will remain in place until the earlier of the start of trading on Thursday, January 31, or an announcement is released to market.
G Medical is well positioned for growth in 2019 with catalysts including first production from its facility in China and increased sales revenue from an expanding global presence.
The mobile and e-health company has received all formal certifications from regulatory bodies to utilise its Guangzhou facility in China for production.
Device production is expected to begin this quarter once all final device componentry has been received for the production line.
This facility will produce the company’s Prizma mobile medical monitor and the G Medical Patch (GMP) products.